nonalcoholic%20fatty%20liver%20disease
NONALCOHOLIC FATTY LIVER DISEASE

Nonalcoholic fatty liver disease is having excessive hepatic fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes.

It is considered as a hepatic manifestation of metabolic syndrome.

Progression of nonalcoholic fatty liver disease is variable.

Introduction

  • Fatty liver is usually an incidental finding on abdominal imaging that reveals hepatic steatosis and laboratory study results of elevated liver enzymes
  • Considered as hepatic manifestation of metabolic syndrome (obesity, type 2 diabetes mellitus, insulin resistance, dyslipidemia and hypertension)
  • Most common liver disorder in the Western countries but less commonly reported in its general population
  • Becoming a serious health issue in many Asian countries
  • Prevalence is 2x higher in males than in females
  • Progression of nonalcoholic fatty liver disease (NAFLD) is variable; ranges from hepatic steatosis through inflammatory nonalcoholic steatohepatitis (NASH) to fibrosis or cirrhosis
  • Major cause of mortality in patients with NAFLD is cardiovascular disease

Definition

  • Excessive hepatic fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes

Signs and Symptoms

  • Patient usually presents asymptomatic but may describe vague right upper quadrant pain, fatigue and malaise

Risk Factors

  • Obesity
  • Insulin resistance/metabolic syndrome
  • High-calorie diet with saturated fats, refined carbohydrates, sugar-sweetened beverages and high fructose
  • Jejunoileal bypass surgery
  • Highest risk in 40-65 years old
  • Higher risk in Hispanics and Asians while lower risk in African-Americans
  • Genetic predisposition
  • Drugs and toxins (eg Amiodarone, Coralgil, corticosteroids, synthetic estrogens, Methotrexate, IV Tetracycline)
  • Polycystic ovary syndrome 
  • Hypothyroidism
  • Obstructive sleep apnea 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.